PATENT CLAIM ANALYSIS

Application Number: 15936686
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "134100"]

Abstract:
The present disclosure relates to a method for the treatment of a non-pathogen associated inflammatory disorders in a subject in need thereof, comprising administering to said subject an isolated peptide which specifically binds to an amino acid sequence within the dimer interface of a T cell costimulatory pathway member, particularly the T cell costimulatory pathway members CD28 and CTLA4. The present disclosure also relates to pharmaceutical compositions comprising the isolated peptide and to use of the peptide in treating of a non-pathogen associated inflammatory disorders.

Claim (Index 287):
The isolated peptide or pharmaceutical composition for use according to any one of  claims 13  to  17 , wherein said isolated peptide or pharmaceutical composition is for administration to a subject in need thereof from about 30 minutes to about 60 or 90 minutes, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 36, 48, 60 or 72 hours, 4, 5, 6, 7, 14, 32 or 28 days following exposure to said radiation.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.7451
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15035571', '15558080', '13392548', '09888324', '14398260']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8049467075080494
- 35 USC 102 Novelty (BERT): 0.6544946276650065
- Combined Prediction Score: 0.7899014995237451
- Mean Citation Score: 509.97055599999993
- Max Citation Score: 840.2424300000001
- Similarity Product: 582.8367719417954

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test